|
1
|
Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase.
|
J Biol Chem
|
2005
|
1.02
|
|
2
|
Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
|
J Biol Chem
|
2012
|
0.96
|
|
3
|
New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.
|
J Med Chem
|
2012
|
0.84
|
|
4
|
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
|
J Med Chem
|
2012
|
0.82
|
|
5
|
Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
|
J Neurochem
|
2014
|
0.80
|
|
6
|
Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig.
|
Pharm Res
|
2013
|
0.77
|
|
7
|
Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
|
FEBS J
|
2014
|
0.76
|